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Background: Methicillin-resistant Staphylococcus aureus (MRSA) is a public health
threat and a major cause of hospital-acquired and community-acquired infections. This
study aimed to investigate the genetic diversity of MRSA isolates from 2015 to 2017 and
to characterize the major MRSA clones and anti-biogram trends in Palestine.
Methodology: Isolates were obtained from 112 patients admitted to different hospitals
of West Bank and East Jerusalem, originating from different clinical sources. Antibiotic
susceptibility patterns, staphylococcal chromosomal cassette mec (SCCmec) typing,
and Staphylococcus aureus protein A (spa) typing were determined. Also, a panel of toxin
genes and virulence factors was studied, including: Panton-Valentine Leukocidin (PVL),
ACME-arcA, Toxic Shock Syndrome Toxin-1 (TSST-1), and Exfoliative Toxin A (ETA).
Results: Of the 112 confirmed MRSA isolates, 100% were resistant to all β-lactam
antibiotics. Resistance rates to other non- β-lactam classes were as the following: 18.8%
were resistant to trimethoprim-sulfamethoxazole, 23.2% were resistant to gentamicin,
34.8% to clindamycin, 39.3% to ciprofloxacin, and 63.4% to erythromycin. All MRSA
isolates were susceptible to vancomycin (100%). Of all isolates, 32 isolates (28.6%) were
multidrug- resistant (MDR). The majority of the isolates were identified as SCCmec type
IV (86.6%). The molecular typing identified 29 spa types representing 12 MLST-clonal
complexes (CC). The most prevalent spa types were: spa type t386 (CC1)/(12.5%),
spa type t044 (CC80)/(10.7%), spa type t008 (CC8)/(10.7%), and spa type t223
(CC22)/(9.8%). PVL toxin gene was detected in (29.5%) of all isolates, while ACME-
arcA gene was present in 18.8% of all isolates and 23.2% had the TSST-1 gene. The
two most common spa types among the TSST-1positive isolates were the spa type t223
(CC22)/(Gaza clone) and the spa type t021 (CC30)/(SouthWest Pacific clone). All isolates
with the spa type t991 were ETA positive (5.4%). USA-300 clone (spa type t008, positive
for PVL toxin gene and ACME-arcA genes) was found in nine isolates (8.0%).
Conclusions: Our results provide insights into the epidemiology of MRSA strains in
Palestine. We report a high diversity of MRSA strains among hospitals in Palestine, with
frequent SCCmec type IV carriage. The four prominent clones detected were: t386-
IV/ CC1, the European clone (t044/CC80), Gaza clone (t223/CC22), and the USA-300
clone (t008/CC8).
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INTRODUCTION
Methicillin-resistant Staphylococcus aureus (MRSA) is an
important bacterial pathogen in both community and healthcare-
related settings in different parts of the world. It is one of the
major human pathogens that can cause broad variety of human
diseases ranging from mild skin and soft tissue infections
(SSTIs) to severe life-threatening invasive infections; such as:
endocarditis, osteomyelitis, necrotizing pneumonia, bacteremia,
septicemia, meningitis, food poisoning, and toxic shock
syndrome (1–5). Methicillin resistance is caused by an alteration
in the penicillin-binding protein (PBP2a) which has a lower
affinity to the β-lactam antibiotics; including: all penicillins, all
cephalosporins (except the fifth generation ceftaroline), and
carbapenems (6, 7). It is encoded by the mecA gene carried on
a staphylococcal chromosomal cassette (SCCmec).Thus; the
therapeutic options of MRSA strains are lowered and limited.
Epidemiologic typing and molecular characterization of
MRSA are crucial to monitor the occurrence and development
of new epidemic clones and to determine intervention policies
(8–10). Since hospital-associated (HA-MRSA) clones differ
from community-associated (CA-MRSA) clones, clonal
characterization is important to determine the source and
the transmission routes of MRSA strains. Different typing
methods are used to characterize different MRSA strains and
clones. Specifically, defining the Staphylococcal Chromosomal
Cassette (SCCmec) type is important to suggest the origin of
the clone either hospital acquired or community acquired. The
SCCmec types: I, II, and III are associated with HA-MRSA
strains while types IV and V are considered as community
associated MRSA strains (11, 12). Staphylococcus aureus protein
A (spa) typing is also frequently used and based on typing
of protein A. The spa typing technique depends on DNA
sequencing of short sequence repeats (SSRs) of the polymorphic
conserved X region of the staphylococcal protein A gene (13).
Additionally, defining which virulence factors a strain may
harbor is important not only for understanding the virulence of
the strain, but also for studying the epidemiology of different
common clones. Among these are: Panton-Valentine Leukocidin
toxin (PVL); a pore-forming cytotoxin that can highly cause
leukocyte destruction and tissue necrosis (14), Toxic Shock
Syndrome Toxin-1 (TSST-1); a superantigen that can mediate
fever, hypotension, rash, multi-organ dysfunction, and lethal
shocks (15), Exfoliative Toxin A (ETA); a toxin that can lead
to hydrolysis of the superficial skin layers leading to cutaneous
infections and staphylococcal scalded skin syndrome (SSSS) (16)
and arcA; a surrogate marker for Arginine Catabolic Mobile
Element (ACME) I. The ACME is related with pathogenicity
of the MRSA isolates which enhances both virulence and the
ability of MRSA to colonize human skin (17). MRSA is a major
public health concern in Palestine and little is known and studied
about its molecular epidemiology and common epidemic clones
(18, 19). This study aimed to investigate the genetic diversity
and virulence genes of MRSA isolates identifying the prominent
clones causing invasive infections in healthcare settings in the
West Bank-Palestine, from 2015 to 2017.
METHODOLOGY
Bacterial Strains and Data Collection
In the present cross sectional descriptive study, a total of 112
MRSA isolates were collected from different sources, including:
wound, blood, nasal swabs, urine, pus, tissue, abscesses, ear
swabs, sputum, and other clinical sources; such as: cerebrospinal
fluid (CSF) culture, central venous pressure (CVP) tip culture,
skin swabs, synovial fluid culture, and trap. The study period
was between 16th of November 2015 and 13th of July 2017
collected from different hospitals distributed in the West Bank-
Palestine. Demographic and clinical data including: age, sex,
place of residence, date of administration and hospitalization,
type of infection, isolate antimicrobial susceptibility testing,
specimen origin, and date of isolation were collected from
medical records. Age was categorized to four age groups, as
the following: infant; from 0 to 1 year, children; from 1 to 10
years, adolescent; from 10 to 19 years and as adult; more than
19 years.
Bacterial Culture and Identification of
MRSA Strains
In the Central Laboratory of Al-Quds Public Health Society,
MRSA isolates were identified phenotypically by colony
morphology on blood agar and coagulase mannitol salt agar
base (CMSA), gram stain, catalase, and coagulase tests. The
methicillin resistant strains were defined by the disk agar
diffusion method using a cefoxitin disk/30 µg. In addition, the
MRSA strains were confirmed by the detection of mecA gene
using PCR as described by Geha et al. (20).
Antimicrobial Susceptibility Testing
The antimicrobial susceptibility testing was performed
using a disk diffusion method according to CLSI (2017)
recommendations (21). Eight antimicrobial agents were tested,
as the following: penicillin G (10 units/disc), cefoxitin (30 µg),
vancomycin (30µg), erythromycin (15µg), clindamycin (10µg),
and gentamicin (10 µg), and trimethoprim-sulfamethoxazole
(25 µg), and ciprofloxacin (5 µg) were determined. Isolates
were defined as multidrug resistance strains (MDR) when they
were resistant to at least three different antibiotic groups in
addition to resistance to the β-lactam antibiotics (22). The D-test
was performed to test the inducible resistance to clindamycin
as needed.
DNA Extraction and Quantification
Genomic DNA was extracted from overnight fresh pure cultures
on blood agar using DNA extraction kit (Nucleospin, Macherey-
Nagel, Düren, Germany) according to the manufacturer’s
instructions (23). Isolates were freezed upon collection, and then
thawed and sub-cultured on BA overnight to be used, later on, for
genomic extraction.
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TABLE 1 | All target genes and primers used in this study.
# Gene OligoaName Primer sequence 5′-3′ Length (bp) Referenceb
1 mecA mecA1Fc GTAGAAATGACTGAACGTCCGATAA 310 (20)
mecA2Rd CCAATTCCACATTGTTTCGGTCTAA
2 SCCmec multiplex ′′4 primers′′ β/ccrA2F-B ATTGCCTTGATAATAGCCYTCT 937 (24)
α3/ccrA2R-B TAAAGGCATCAATGCACAAACACT
ccrCF/ccrC CGTCTATTACAAGATGTTAAGGATAAT 518 (24)
ccrCR/ccrC CCTTTATAGACTGGATTATTCAAAATA
1272F1/IS1272 GCCACTCATAACATATGGAA 415 (12)
1272R1/IS1272 CATCCGAGTGAAACCCAAA
5RmecAF/IS431 TATACCAAACCCGACAACTAC 359
5R431R/IS431 CGGCTACAGTGATAACATCC
3 Spa 1095F/spa-F AGACGATCCTTCGGTGAGC 200–400 (25)
1017R/spa-R GCTTTTGCAATGTCATTTACTG
4 PVL luk-PV-1F/PVL ATCATTAGGTAAAATGTCTGGACATGATCCA 433 (26)
luk-PV-2R/PVL GCATCAASTGTATTGGATAGCAAAAGC
5 TSST-1 GTSSTR-1F ACCCCTGTTCCCTTATCATC 350 (27)
GTSSTR-2R TTTTCAGTATTTGTAACGCC
6 ETA GETAR-1F GCAGGTGTTGATTTAGCATT 93 (27)
GETAR-2R AGATGTCCCTATTTTTGCTG
7 ACME-arcA arcA-F GAGCCAGAAGTACGCGAG 724 (28)
arcA-R CACGTAACTTGCTAGAACGAG
aOligo, Oligonecleotide.
bReference.
cF, Forward primer.
dR, reverse primer.
Molecular Characterization of MRSA
Strains
PCR Identification of Staphylococcal Cassette
Chromosome (SCCmec) Types
SCCmec types (I–V) were identified by multiplex PCR as
described by Boye et al. (12). The primers used in this multiplex
PCR assay are shown in Table 1.
Identification of spa Types
All MRSA isolates were characterized by spa sequence-based
typing using the PCR primers and cycling as previously described
by Shopsin et al. (Tables 1, 2) (25). All spa amplicons were
sequenced (Hylabs, Rehovot, Israel) and analyzed using the spa
Type Finder/Identifier: (http://spatyper.fortinbras.us/). Then, the
Based Upon Repeat Pattern (BURP) algorithm of the Staph-
Type
TM
software (Ridom GmbH, Münster, Germany) was
used for clustering of spa types and grouping in spa-clonal
complexes (spa-CC).
PCR Identification of Staphylococcal Genes for
Virulence Factors
Genes for virulence factors, namely: PVL cytotoxin genes (lukS
and lukF), TSST-1 (encoded by tst gene), ETA (encoded by
eta), and arcA (a surrogate marker for ACME I in the arc gene
cluster) were tested using PCR for all isolates. These virulence
factors and staphylococcal toxin genes were identified by singular
PCRs with amplicons of: 433, 350, 93, and 724 bp, respectively
(Table 1) (26–28).
PCR Assay and Visualization
All PCR reactions were optimized and carried by the Basic
Gradient Thermocycler (BiometraTProfessional, Jena,
Germany)using ready mix (Syntezza, Israel) according to
the manufacturer’s instructions, (Table 2) (29). Amplicons for all
the characterized genes were analyzed electrophoretically
in 2% agarose gels and visualized by UV light using
a gel documentation system (Bio-Imaging Systems
Mini-Lumitransilluminator, Germany).
Statistical Analysis
All data were analyzed using the Statistical Package for Social
Sciences (SPSS) version 20, using Chi-square test. A p-value of
< 0.05 was considered to be statistically significant.
RESULTS
Bacterial Isolates and Study Population
From November 2015 to July 2017, a total of 112 MRSA isolates
were collected from major hospitals in the West Bank-Palestine.
The majority of isolates was collected from Al-Makassed Islamic
Charitable Hospital (n = 77, 68.8%). Place of residence for all
included patients were documented. The most frequent regions
of residence were patients from Gaza and Jerusalem (29.5% for
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TABLE 2 | Thermal cycler programs used for the amplification of the targeted genes and toxins in this study.
# Target
Gene
PCR program (Tempa◦C/Time)-35 cycles Reference
Initial denaturation Denaturation Annealing Extension Final extension
1 mecA 95◦C/5 minb 95◦C/30 sc 58◦C/30 s 72◦C/80 s 72◦C/10min (20)
2 SCCmec 95◦C /5min 94◦C/30 s 55◦C/30 s 72◦C/80 s 72◦C/10min (12)
3 spa 95◦C/5min 95◦C/30 s 58◦C/30 s 72◦C/45 s 72◦C/10min (25)
4 lukS/lukF 95◦C/5min 95◦C/45 s 55◦C/15 s 72◦C/30 s 72◦C/10min (26)
5 tst 95◦C/5min 95◦C/2min 54◦C/2min 72◦C/2min 72◦C/10min (27)
6 eta 95◦C/5min 95◦C/2min 54◦C/2min 72◦C/2min 72◦C/10min (27)
7 arcA 95◦C/5min 94◦C/20 s 55◦C/30 s 72◦C/30 s 72◦C/10min (28)
aTemp, Temperature.
bmin, Minutes.
cs, Seconds.
each), followed by Hebron (13.4%), Nablus (10.7%), Ramallah
(10.7%), Bethlehem (4.5%), Tubas (0.9%), and Tulkarem (0.9%).
According to gender, sixty MRSA isolates (53.6%) were obtained
from males and 41(36.6%) were obtained from females. Gender
of 9.8% of the isolates was not reported. The mean age was
33 years with the oldest case being an 85 years old female and
the youngest a 2 months years old female. The most common
age group was adults (60.7%), followed by adolescents (14.3%),
infants (8.9%), and children (7.1%). Of the adults, most were
older than 30 years old, while age was not found for 8.9% of the
samples. Samples were collected from different clinical sources.
The highest number of isolates were obtained from wound
infections (35.7%), followed by: blood culture (12.5%), nasal
swabs (8.9%), urine culture (8.9%), pus culture (5.4%), tissue
culture (4.5%), abscess (3.6%), ear swabs (2.7%), and sputum
culture (2.7%). One MRSA isolate was collected and reported
from a CSF culture (0.9%) which is extremely alarming and
important in whichMRSA strains are reaching the CSF leading to
significant bacterial meningitis. Moreover, MRSA was obtained
from other sources (4.5%), as the follows: axillary swab (0.9%),
CVP culture (0.9%), skin swab culture (0.9%), synovial fluid
culture (0.9%), and trap (0.9%). Source of eleven isolates (9.8%)
was not identified.
Detection of MRSA by Cefoxitin Disk
Diffusion Test and mecA Gene
All isolates (100%) were verified as Methicillin Resistant
Staphylococcus aureus using the cefoxitin disc resistance
(<22mm) and confirmed as MRSA using PCR targeting the
mecA gene yielding to 310 bp clear band.
Antimicrobial Susceptibility Patterns
Resistance rates to non β-lactam antibiotics were as the following:
18.8% were resistant to trimethoprim-sulfamethoxazole, 23.2%
were resistant to gentamicin, 34.8% to clindamycin, 39.3%
to ciprofloxacin, and 63.4% to erythromycin. Interestingly,
the susceptibility of MRSA isolates to gentamicin and
Trimethoprim/sulfamethoxazole (SXT) was the highest (76.8,
81.2%), respectively. All isolates were susceptible to Vancomycin
(100%). Of all the isolates, 32 were MDR (Figure 1).
FIGURE 1 | Antimicrobial resistance rates among all MRSA isolates in this
study.
The antimicrobial resistance rates among the MRSA spa types
were studied. The resistance rates of the MRSA isolates against
erythromycin, were significantly high in the spa type t386 (p
< 0.005), followed by the spa types: t008 (8.9%), t044 (5.4%),
t021 (5.4%), and t223 (4.5%). Similarly, the resistance rates of
MRSA isolates against clindamycin were high in the spa types:
t386 (7.1%) and t008 (4.5%), followed by t044 (3.6%), and t021
(2.7%). Moreover, the resistance rates of MRSA isolates against
ciprofloxacin and gentamicin were found significantly high (p <
0.05) in the spa type t037 (7.1% for each). Also, for the spa types
t008 and t044, they have shown a significant high resistance rate
to ciprofloxacin (p < 0.05).
Molecular Characterization and Typing of
Isolates
SCCmec Typing
Among all MRSA isolates, ninety seven isolates belonged to
SCCmec type IV (86.6%) and one belonged to SCCmec type V
(0.9%). These isolates identified as CA-MRSA when carrying the
SCCmec types IV or V. Ten isolates belonged to SCCmec type
I (8.9%) and identified as HA-MRSA. Both SCCmec type II and
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FIGURE 2 | Frequency of all spa-types found in this study.*Other spa-types: t005, t011, t018, t084, t085, t1094, t121, t1247, t127, t314, t318, t359, t541, t605,
t648, and t932 were found in a frequency of one for each isolate (0.9% for each) with four isolates (3.6%) non-typeable (err) isolates.
SCCmec type III were not detected among isolates. Four MRSA
isolates (3.6%) could not be SCCmec typed and designated as
non-typeable (NT).
Spa Typing
A total of twenty nine spa types were identified. The size of
the amplified DNA for spa typing ranged between 200 and
450 bp. Five spa types: t386, t008, t044, t223, and t037 were
predominant and represented (12.5%), (10.7%), (10.7%), (9.8%),
(8.9%) of isolates, respectively (Figure 2). There was a wide
range of clonal varieties, with twelve MLST clonal complexes
(CCs) were identified. This was done with regard to the BURP
analysis. The 12 identified MLST-CCs were: CC22, CC1, CC8,
CC80, CC8/239, CC30, CC5, CC913, CC6, CC121, CC126,
and CC15. The CC22 (15.2%), CC1 (13.4%), CC8 13.4%),
and CC80 (13.4%) were predominant, followed by CC8/239
(8.9%), CC30 (8.0%), CC5 (8.0%), CC913 (5.4%), CC6 (2.7%),
CC121 (0.9%), and CC126 (0.9%).Unfortunately, ten isolates
(8.9%) were not found using the BURP analysis. However, the
identifiedMLST-CCswere distributed among the spa types where
a single clonal complex could contain more than one spa type as
shown in Table 3.
Toxin Genes Profiling
Detection of PVL Toxin
Of all MRSA isolates, thirty three (29.5%) were positive for PVL
toxin gene. All the PVL positive MRSA isolates belonged to
SCCmec type IV. PVL was detected among eleven spa types:
t044, t008, t223, t021, t002, t131, t104, t084, t121, t318, and t386.
Two spa types (t044 and t008) among PVL positive isolates were
predominant and represent (11/12 t044, CC80: PVL+; European
clone) and (10/12 t008, CC8: PVL +; USA-300 clone) isolates,
respectively. Out of 11 isolates of the spa type t223, only one
isolate was positive for the PVL toxin gene (1/11 isolates t223,
CC22: PVL+) and classified as a “Unique Gaza Strain.”
Detection of ACME-arcA Gene
The gene coding for the ACME-arcA was detected in 18.8 %
(21/112) of isolates where 20 isolates harbored the SCCmec type
IV, and one isolate harbored the SCCmec type I. It was detected
among nine spa types: t008, t991 t037, t104, t1094, t1247, t1516,
t223, and t386. Whereas, out of the 12 isolated identified as spa
type t008, nine isolates were ACME-arcA positive (9/12 t008,
CC8: ACME-arcA). These nine isolate were also PVL positive and
classified as: USA-300 clone.
Detection of TSST-1
Similarly, 26.8% of the MRSA isolates (30/112) tested positive
for the presence of the TSST- where 25 isolates belonged to the
SCCmec type IV; while the other TSST-1 positive isolate belonged
to SCCmec type I. This toxin was detected among eleven spa
types: t223, t021, t1516, t002, 1005, t008, t018, t386, t541, t991,
and t605. The two most common spa types among TSST-
1positive isolates were: the spa type t223 and t021. Out of the
11 identified isolated as spa type t223, nine t223 MRSA isolates
were significantly (p < 0.05) TSST-1 positive (9/11 t223, CC22:
TSST-1+; Gaza clone) which was commonly typed previously as
“Gaza clone” in Gaza region. Notably, all the seven isolates with
spa type t021 were TSST-1 positive (100%) and classified as South
West Pacific clone.
Table 4 summarized the common MRSA clones with
antibiotic resistance according to their SCCmec types, spa types
and toxin genes profile.
Detection of ETA
The gene coding for the exfoliative toxin A (eta) was detected in
5.3% of all the MRSA isolates harboring the spa type t991/CC913.
All the other spa types were negative for ETA. Among the 6
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TABLE 3 | The MLST-CCs and the related spa types found in this study by the
BURP.
# MLST-CCas spa types No. of isolates (%)
1 CC22 t223 11(9.8%)
t1516 4 (3.6%)
t005 1 (0.9%)
t541 1 (0.9%)
2 CC1 t386 14 (12.5%)
t127 1 (0.9%)
3 CC8 t008 12 (10.7%)
t121 1 (0.9%)
t359 1 (0.9%)
t648 1 (0.9%)
4 CC80 t044 12 (10.7%)
t131 3 (2.7%)
5 CC8/239b t037 10 (8.9%)
6 CC30 t021 7 (6.3%)
t018 1 (0.9%)
t318 1 (0.9%)
7 CC5 t002 4 (3.6%)
t688 3 (2.7%)
t104 2 (1.8%)
8 CC913 t991 6 (5.4%)
9 CC6 t304 3 (2.7%)
10 CC121 t314 1 (0.9%)
11 CC126 t605 1 (0.9%)
12 CC15 t084 1 (0.9%)
13 NFc t011 1 (0.9%)
t085 1 (0.9%)
t1094 1 (0.9%)
t1247 1 (0.9%)
t932 1 (0.9%)
(*)? 1 (0.9%)
(*)?, This spa-type was not identified on the spa database website; (http://spatyper.
fortinbras.us/).
aClonal Complexes.
bThe spa-t037 found to be CC8 or CC239 by the BURP, MLST is recommended for
finite identification.
cNot Found by BURP.
isolates with the spa type t991, five isolates were of SCCmec type
IV, and one isolate was belonged to SCCmec type I. None of the
spa t991; eta positive isolates were harboring the PVL toxin, and
only one isolate was positive for ACME-arcA while 4/6 spa t991
isolates harbored the TSST-1.
DISCUSSION
Methicillin Resistant Staphylococcus aureus (MRSA) is a serious
life threatening pathogen in hospitals and among healthy
populations (29–32). Thus, the characterization of these strains
is important for local epidemiology and surveillance studies.
Little is known about MRSA types and clones in Palestine.
This study was conducted to characterize the molecular and
the antimicrobial profile of MRSA isolates in regions of West
Bank, from 2015 to 2017. Most isolates were obtained from
Al- Makassed Islamic Charitable Society Hospital (68.8% of all
isolates). Al-Makassed is one of the most important leading
medical institutions in Palestine that provides medical services to
all Palestinians in the West Bank, Gaza Strip and East Jerusalem.
In a recent study conducted at Al-Shifa hospital in Gaza Strip
for the nasal colonization of MRSA, a carriage rate of MRSA
among the health care workers who are in contact with the
vulnerable patient in the hospitals were equal to 25.5% (33).This
highlights that there is a high carriage rate of MRSA among
the Palestinian populations. Moreover, it has been reported that
carriage of MRSA is a major risk factor for transmission and
subsequent infections that may develop to systemic or severe
infections (34, 35).
Here, 32 MRSA isolates were MDR (28.6%). In comparison
with other reports based on the same definition, a higher MDR
resistance rate (60.0%) was also reported in Israel (36). However,
our highest antibiotic susceptibility patterns were noticed among
SXT (81.3%), followed by gentamicin (76.8%), and ciprofloxacin
(65.2%). This may aid medical laboratory technologist to test the
susceptibility of these antibiotics to be used as major and first
line therapeutic options for the treatment of MRSA infections.
NoVancomycin Resistance Staphylococcus aureus (VRSA) strains
were reported, where the physicians can still prescribe this
antibiotic based on empirical therapy when needed, especially for
urgent infections. At the molecular level, the predominantMRSA
strains in our region are community associated (SCCmec type IV,
86.6%). SCCmec type IV is the smallest structural type among the
SCCmec types and believed to be the most mobile version that is
associated with CA-MRSA infections (37). About one third of the
CA-MRSA strains isolated in our study were harboring the PVL
toxin gene (32/97 SCCmec type IV). This indicates that the CA-
MRSA strains among Palestinian population are highly virulent
with invasive. This can give us an indication that we may have a
high carriage of MRSA among healthy population or the health
care workers in our region. These CA-MRSA strains could be
carried as a normal flora in skin, hands, and groin or in the nasal
cavity of the health care workers or the patients themselves, but
when these patients are hospitalized or have an opened wound
or surgery, their immunity may fall down allowing this normal
flora or colonization to cause secondary opportunistic infections.
Therefore, hand hygiene and infectious control programs must
be applied well in our hospitals. This interface may serve as a
causative agent of cross contamination of hospital acquired and
community acquired MRSA infections.
This agreed with a study done in Copenhagen where Bartels
and his colleagues reported that there is a rapid shift to CA-
MRSA, where SCCmec type IV was found in (86%) of isolates
(38). Moreover, a significant presence of MRSA was seen. In
this study, 62 hospitals were included showing an evidence of
endemicity of MRSA in these regions (39). Also, it has been
reported that there is an introduction of several MRSA strains
with intercontinental exchange of new MRSA clones in the
Middle East (40). In a recent study conducted in Gaza by Al
Laham and his colleagues, similar results were obtained with
a high frequency of the SCCmec type IV, which accounted for
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TABLE 4 | Common MRSA clones with antibiotic resistance according to their SCCmec types, spa types and toxin genes profile found in this study.
MRSA Clone n % spa type/CC SCCmec Virulence factors *% Antibiotic resistance
PVL TSST-1 arcA E C CN CIP SXT
t386-IV 14 12.5 t386/CC1 IV neg neg neg 100 57.1 21.4 21.4 0
The European clone 11 9.8 t044/CC80 IV pos neg neg 50 33.3 16.7 41.7 16.7
The Gaza clone 10 8.9 t223/CC1 IV neg pos neg 45.5 18.2 18.2 9.1 27.3
t037-IV 10 8.9 t037/ CC8/239 IV neg neg neg 40 20 80 80 10
USA-300 clone 9 8 t008/CC8 IV pos neg pos 83.3 41.7 0 75 8
* :E, Erythromycin; C, Clindamycin; CN, Gentamicin; CIP, Ciprofloxacin; SXT, Trimethoprim sulfamethoxazole.
(79.3%) of MRSA isolates. Al Laham has found that the most
dominant spa types were t223 and t044 where seven isolates were
belonged to the spa type t223, in which one of these isolates was
called as a “unique Gaza strain” harboring the PVL toxin gene,
while all the other isolates with the spa type t223 did not carry
the PVL toxin gene (19). This was in a high agreement with
our findings with an isolate with a similar pattern as the unique
Gaza strain with spa type t223, SCCmec type IV, PVL positive,
and TSST-1 negative. Notably, the Gaza clone (t223) with TSST-1
positive, CC22, and SCCmec type IV was detected in the isolates
collected from Al- Makassed Islamic Charitable Society Hospital
only. Six isolates were from Gaza patient and five isolates were
from patients living in Jerusalem and its suburbs. Interestingly,
this could be explained due the transmission of the Gaza clone
to other Palestinian populations as Gaza patients were referred to
Al- Makassed Islamic Charitable Society Hospital in Jerusalem.
Moreover, the spa type t223 was also reported in other countries
as Kuwait, Egypt and Saudi Arabia. This transmission could be
due to the national travels between these countries (41–45).
The spa type t008 was predominant in 12 MRSA isolates.
Nine of them were related to the USA-300 clone, harboring
both the PVL and the ACME-arcA genes (8% of all isolates).
This clone is a common cause of SSTIs and was considered as
the most widespread CA-MRSA clone in the United States that
emerged in the late 1990s. This clone is a significant and dramatic
epidemic clone due to its carriage of virulence and resistance
determinants that may enhance severity and pathogenicity of the
isolated strain (17). The carriage of PVL toxin gene among the
CA-MRSA strains, especially the USA-300 clone, is crucial and
make these strains hyper-virulent which may cause occasionally
fatal infections (46). To the best of our knowledge, our study
is the first study that has characterized the presence of the
USA-300 clone in the Palestinian regions. Also, due to the shift
of MRSA infections to the community and the high carriage
among populations, no individual can be considered not at
risk for CA-MRSA infection. This worthy point needs further
attention because meaningful results and control programs can
be achieved. Regarding the appropriate treatment approaches,
culturing is recommended for the MRSA infections because
it is the only ideal predictor of the appropriate antibiotics
therapy. Educational and public awareness, medical education,
professional development, and training are recommended for
the public society, parents, pharmacists, medical laboratories
and physicians for reliable, appropriate and proper antibiotic
therapy decisions. This can help to minimize the development
for more complicated resistant MRSA strains in hospitals and
may save many immunocompromized hospitalized patients.
All together, these points suggest the need for efficient future
surveillance studies and infection control strategies. Moreover,
these strategies can improve the economic impact becauseMRSA
is considered as a serious economic burden on the healthcare
resource and associated with increased hospitalization costs
due to the prolonged course on more complex antibiotics and
extended hospital days.
The results of this study showed that all the PVL-positive
MRSA isolates (29.5% of all isolate) recovered from these
hospitals as part of the present investigation were CA which is
confirming as an earlier preliminary observation that CA-MRSA
is an emerging problem in Palestine. Some reports have suggested
that certain strains of CA-MRSA may be more virulent than
HA-MRSA (47, 48). The expression of PVL, cytolytic toxin that
targets mononuclear and polymorphonuclear cells and causes
cell death by necrosisor apoptosis, has been strongly linked with
CA-MRSA (49).
Similarly, TSST-1 and ACME-arcA genes were detected in
23.2 and 18.8% of all isolates, respectively. These were relatively
high in comparison with a similar study conducted in China
where they found the PVL and TSST-1 genes in 11.3 and 18.8%,
respectively (50). For the ACME-arcA carriage, this was in
agreement with a study conducted in Armenia which found the
ACME-arcA in 15% of all MRSA isolates, but contraindicated
with the carriage of the PVL toxin gene where they did not
detected the PVL toxin gene in any of their MRSA isolates
(51). This indicates that there is a high carriage of PVL,
ACME-arcA, TSST-1, and ETA genes among MRSA strains
in Palestine.
CONCLUSION
The phenotypic and genotypic diversity with harboring several
virulence factors and toxin genes by MRSA isolates in Palestine
is crucial. This study indicates that we have unique MRSA
strains which may be associated with more complicated
infections and associated with more social and economic
burdens. Thus, there is an urgent need to develop better
measurements among clinical microbiology laboratories for
proper detection, identification, and reporting of MRSA isolates
with deep knowledge among physicians toward antibiotic
stewardship and prescription practices for this multi-drug
resistant organism. These together may control and limit the
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development and spread of new clones and more complicated
MRSA infections.
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